Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers

• Status: Unknown status
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to identify genetic, brain morphologic, and environmental biomarkers that contribute to the pathophysiology of attention-deficit/hyperactivity disorder (ADHD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Childrens Hospital
• Treatments: Atomoxetine Hydrochloride; Methylphenidate

Criteria

Inclusion Criteria:

• A diagnosis of attention-deficit/hyperactivity disorder confirmed using the Kiddie-Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version- Korean Version (K-SADS-PL-K).

• IQ over 70

Exclusion Criteria:

• Intelligence quotient (IQ) < 70

• A hereditary genetic disorder

• A current/past history of brain trauma, organic brain disorder, seizure, or any neurological disorder

• Autism spectrum disorder, communication disorder, or learning disorder

• Schizophrenia or any other childhood-onset psychotic disorder

• Major depressive disorder or bipolar disorder

• Tourette's syndrome or chronic motor/vocal tic disorder

• obsessive-compulsive disorder

• A history of methylphenidate treatment lasting more than 1 year or received within the previous 4 weeks